Agios Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:AGIO
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 269 out of 851
Universe
Global Universe 8521 out of 15094
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Catalyst Pharmaceuticals, Inc. |
24.3
Medium
|
166 out of 851 |
Agios Pharmaceuticals, Inc. |
26.6
Medium
|
269 out of 851 |
Scholar Rock Holding Corp. |
28.9
Medium
|
394 out of 851 |
Vera Therapeutics, Inc. |
35.3
High
|
671 out of 851 |
Geron Corp. |
37.5
High
|
764 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Agios Pharmaceuticals, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Agios Pharmaceuticals, Inc.'s Management of ESG Material Risk is Average